<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" nameag="viewport"/>
<title>Anti HIV Drugs</title>
<script src="https://cdn.tailwindcss.com"></script>
<script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
<script src="https://cdn.jsdelivr.net/npm/canvas-confetti@1.6.0/dist/confetti.browser.min.js"></script>
<style>
        /* Custom styles for enhanced aesthetics and responsiveness */
        .option-btn {
            transition: all 0.3s ease;
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
        }
        .option-btn:hover, .option-btn:active {
            transform: scale(1.02);
            box-shadow: 0 4px 8px rgba(0, 0, 0, 0.2);
        }
        .option-btn.selected {
            background-color: #3b82f6;
            color: white;
        }
        .marked {
            background-color: #fef08a;
        }
        .progress-bar {
            transition: width 0.5s ease-in-out;
            background: linear-gradient(to right, #3b82f6, #22c55e);
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.2);
            animation: pulse 2s infinite;
        }
        @keyframes pulse {
            0% { opacity: 1; }
            50% { opacity: 0.8; }
            100% { opacity: 1; }
        }
        .question-nav-btn, .result-nav-btn-grid {
            width: 40px;
            height: 40px;
            display: flex;
            align-items: center;
            justify-content: center;
            border-radius: 8px;
            font-size: 16px;
            touch-action: manipulation;
            transition: all 0.2s ease;
        }
        .question-nav-btn:hover, .question-nav-btn:active, .result-nav-btn-grid:hover, .result-nav-btn-grid:active {
            transform: scale(1.05);
        }
        .answered {
            background-color: #22c55e;
            color: white;
        }
        .unanswered {
            background-color: #e5e7eb;
        }
        .marked-nav {
            border: 2px solid #fef08a;
        }
        .video-container, .audio-container {
            display: none;
            position: relative;
        }
        .video-container.active, .audio-container.active {
            display: block;
            animation: fadeIn 0.5s ease-in;
        }
        @keyframes fadeIn {
            from { opacity: 0; }
            to { opacity: 1; }
        }
        .section-transition {
            transition: opacity 0.3s ease;
        }
        .section-transition.hidden {
            opacity: 0;
            pointer-events: none;
        }
        .result-nav {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-top: 1rem;
        }
        .result-nav-btn {
            background-color: #4b5563;
            color: white;
            padding: 0.5rem 1rem;
            border-radius: 8px;
            transition: all 0.2s ease;
        }
        .result-nav-btn:hover, .result-nav-btn:active {
            background-color: #374151;
            transform: scale(1.05);
        }
        .result-nav-btn:disabled {
            background-color: #d1d5db;
            cursor: not-allowed;
        }
        .error-message {
            color: #dc2626;
            font-weight: bold;
            margin-top: 1rem;
        }
        /* Mobile-specific adjustments */
        @media (max-width: 640px) {
            .question-nav-btn, .result-nav-btn-grid {
                width: 38px;
                height: 38px;
                font-size: 14px;
            }
            .nav-panel, .results-nav-panel {
                width: 100%;
                max-width: 100%;
                overscroll-behavior: contain;
            }
            .option-btn {
                padding: 12px;
                font-size: 14px;
            }
            .header-text {
                font-size: 1.5rem;
            }
            .subheader-text {
                font-size: 0.875rem;
            }
            .button-group, .result-nav {
                flex-direction: column;
                gap: 0.5rem;
            }
            .result-nav-btn {
                width: 100%;
                text-align: center;
            }
        }
        /* Dark mode styles */
        .dark .bg-gray-100 {
            background-color: #1f2937;
        }
        .dark .bg-white {
            background-color: #374151;
        }
        .dark .text-gray-700 {
            color: #d1d5db;
        }
        .dark .text-gray-800 {
            color: #e5e7eb;
        }
        .dark .bg-gray-200 {
            background-color: #4b5563;
        }
        .dark .border {
            border-color: #4b5563;
        }
        .dark .bg-blue-500 {
            background-color: #2563eb;
        }
        .dark .hover\:bg-blue-600:hover {
            background-color: #1d4ed8;
        }
        .dark .bg-yellow-300 {
            background-color: #b45309;
            color: white;
        }
        .dark .hover\:bg-yellow-400:hover {
            background-color: #92400e;
        }
        .dark .bg-green-500 {
            background-color: #15803d;
        }
        .dark .hover\:bg-green-600:hover {
            background-color: #166534;
        }
        .dark .bg-gray-500 {
            background-color: #4b5563;
        }
        .dark .hover\:bg-gray-600:hover {
            background-color: #374151;
        }
        .dark .result-nav-btn, .dark .result-nav-btn-grid {
            background-color: #2563eb;
        }
        .dark .result-nav-btn:hover, .dark .result-nav-btn:active, .dark .result-nav-btn-grid:hover, .dark .result-nav-btn-grid:active {
            background-color: #1d4ed8;
        }
        .dark .result-nav-btn:disabled, .dark .result-nav-btn-grid:disabled {
            background-color: #4b5563;
        }
        .video-placeholder {
            width: 400px;
            height: 300px;
            background-color: #f0f0f0;
            display: flex;
            align-items: center;
            justify-content: center;
            cursor: pointer;
            margin-top: 10px;
            border-radius: 8px;
            border: 1px solid #ccc;
        }
        .play-icon {
            font-size: 40px;
            color: #007bff;
        }
        .video-loading {
            position: absolute;
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%);
            border: 4px solid #f3f3f3;
            border-top: 4px solid #3b82f6;
            border-radius: 50%;
            width: 40px;
            height: 40px;
            animation: spin 1s linear infinite;
        }
        @keyframes spin {
            0% { transform: translate(-50%, -50%) rotate(0deg); }
            100% { transform: translate(-50%, -50%) rotate(360deg); }
        }
    </style>

<script>
    // --- GEMINI AUTO-CAPTURE LISTENER ---
    // This function runs immediately after the quiz determines an answer is INCORRECT.
    function captureMistake(questionIndex, questionsData) {
        try {
            const item = questionsData[questionIndex];
            // Use the question text as a unique, stable identifier
            const uniqueId = 'srs_quiz_' + btoa(item.text.substring(0, 50)).replace(/=/g, ''); 

            // 1. Clean and simplify the explanation for storage
            let explanationText = item.explanation || item.correct_answer || "No explanation provided.";
            
            // Strip complex HTML (images, lists) and boilerplate text
            explanationText = explanationText.replace(/<img[^>]*>/g, "[IMAGE]").trim(); // Replace images with placeholder
            explanationText = explanationText.replace(/<p><strong>Ans\. [A-Z]\).*/i, "").trim(); // Remove the repeated Answer line
            explanationText = explanationText.replace(/<p><strong>Educational Objective:<\/strong>.*?<\/p>/gs, "").trim(); // Remove EO block
            explanationText = explanationText.replace(/@dams_new_robot/g, "");
            explanationText = explanationText.replace(/<\/?[^>]+(>|$)/g, " ").trim(); // Final strip of remaining tags

            // 2. Prepare card data
            const cardData = {
                text: item.text,
                answer: item.correct_answer,
                explanation: explanationText.substring(0, 500), // Keep explanations short
                nextReview: 0, // Due immediately
                reviews: 0,
                source: document.title.split('-')[0].trim() || 'Quiz'
            };

            // 3. Save to Local Storage (SRS Bank)
            localStorage.setItem(uniqueId, JSON.stringify(cardData));
            
            console.log(`ðŸ§  Captured Mistake #${questionIndex + 1} from ${document.title}`);

        } catch (e) {
            console.error("SRS Capture Failed:", e);
        }
    }
    // --- END GEMINI AUTO-CAPTURE LISTENER ---
</script>

</head>
<body class="bg-gray-100 font-sans transition-colors duration-300 min-h-screen overflow-y-auto">
<!-- Header Section -->
<header class="bg-blue-600 text-white p-4 shadow-lg">
<div class="container mx-auto">
<h1 class="text-2xl md:text-3xl font-bold header-text">Anti HIV Drugs</h1>
<p class="mt-2 text-sm md:text-base subheader-text">
                13 Questions | 13 Total Marks | 23 min Duration | ~106.15 sec/question
            </p>
<button class="mt-2 bg-gray-200 text-gray-800 px-3 py-1 rounded-lg hover:bg-gray-300 transition dark:bg-gray-600 dark:text-white" id="theme-toggle">
                Toggle Dark Mode
            </button>
</div>
</header>
<!-- Instructions Section -->
<section class="container mx-auto p-4 md:p-6 section-transition" id="instructions">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-xl font-semibold mb-4">Instructions</h2>
<ul class="list-disc list-inside space-y-2 text-gray-700">
<li>This test contains 13 multiple choice questions.</li>
<li>Each question has only one correct answer.</li>
<li>You will have 23 minutes to complete the test.</li>
<li>Click or tap on an option to select your answer.</li>
<li>Use the "Mark for Review" button to revisit questions.</li>
<li>Navigate using Previous/Next buttons or the Questions Navigation panel.</li>
<li>Click "Submit" to finish and view results.</li>
<li>The test will auto-submit when time runs out.</li>
</ul>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="start-test">Start Test</button>


</div>
<div class="error-message hidden" id="error-message"></div>
</div>
</section>
<!-- Quiz Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="quiz">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<!-- Progress Bar -->
<div class="w-full bg-gray-200 rounded-full h-3 mb-4">
<div class="progress-bar h-3 rounded-full" id="progress-bar" style="width: 0%"></div>
</div>
<!-- Question Header -->
<div class="flex flex-col md:flex-row justify-between items-center mb-4">
<h2 class="text-lg font-semibold" id="question-number">Question <span>1</span> of 13</h2>
<p class="text-lg font-semibold mt-2 md:mt-0" id="timer">Time Remaining: <span>00:00</span></p>
</div>
<!-- Question Content -->
<div class="mb-6" id="question-content">
<p class="text-gray-800 mb-4" id="question-text"></p>
<div class="flex flex-wrap gap-4 mb-4" id="question-images"></div>
<div class="space-y-3" id="options"></div>
</div>
<!-- Navigation Buttons -->
<div class="flex flex-col md:flex-row justify-between items-center gap-2 md:gap-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition w-full md:w-auto" disabled="" id="previous-btn">Previous</button>
<button class="bg-yellow-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-yellow-400 transition w-full md:w-auto" id="mark-review">Mark for Review</button>
<button class="bg-blue-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="next-btn">Next</button>
<button class="bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full md:w-auto" id="nav-toggle">Questions Navigation</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="submit-test">Submit Test</button>
</div>
</div>
</section>
<!-- Results Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="results">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-2xl font-semibold mb-4">Anti HIV Drugs - Results</h2>
<div class="grid grid-cols-1 md:grid-cols-2 gap-4 mb-6">
<p><strong>Correct:</strong> <span id="correct-count">0</span></p>
<p><strong>Wrong:</strong> <span id="wrong-count">0</span></p>
<p><strong>Unanswered:</strong> <span id="unanswered-count">0</span></p>
<p><strong>Marked for Review:</strong> <span id="marked-count">0</span></p>
</div>
<h3 class="text-lg font-semibold mb-4" id="result-question-number">Question <span>1</span> of 13</h3>
<div class="space-y-6" id="results-content"></div>
<div class="result-nav">
<button aria-label="Previous question result" class="result-nav-btn" disabled="" id="prev-result">Previous</button>
<button aria-label="Toggle results navigation panel" class="result-nav-btn" id="results-nav-toggle">Results Navigation</button>
<button aria-label="Next question result" class="result-nav-btn" id="next-result">Next</button>
</div>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="take-again">Take Again</button>
<button class="bg-gray-500 text-white px-6 py-2 rounded-lg hover:bg-gray-600 transition" id="review-test">Review Test</button>
</div>
</div>
</section>
<!-- Exit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="exit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Leave Test?</h2>
<p class="text-gray-700 mb-4">Your progress will be lost if you leave this page. Are you sure you want to exit?</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="continue-test">No, Continue</button>
<button class="bg-red-500 text-white px-4 py-2 rounded-lg hover:bg-red-600 transition" id="exit-test">Yes, Exit</button>
</div>
</div>
</div>
<!-- Submit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="submit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Confirm Submission</h2>
<p class="text-gray-700 mb-2">You have attempted <span id="attempted-count">0</span> of 13 questions.</p>
<p class="text-gray-700 mb-4"><span id="unattempted-count">0</span> questions are unattempted.</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="cancel-submit">Cancel</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-green-600 transition" id="confirm-submit">Submit Test</button>
</div>
</div>
</div>
<!-- Quiz Navigation Panel -->
<div class="fixed inset-y-0 right-0 nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="nav-panel">
<h2 class="text-lg font-semibold mb-4">Questions Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-nav">Close</button>
</div>
<!-- Results Navigation Panel -->
<div class="fixed inset-y-0 right-0 results-nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="results-nav-panel">
<h2 class="text-lg font-semibold mb-4">Results Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="results-nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="results-nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-results-nav">Close</button>
</div>
<!-- JavaScript Logic -->
<script>
        // Enable debug mode for detailed logging
        const DEBUG_MODE = true;

        // Log debug messages
        function debugLog(message) {
            if (DEBUG_MODE) {
                console.log(`[DEBUG] ${message}`);
            }
        }

        // Initialize questions with error handling
        let questions = [];
        let currentResultQuestion = 0; // State for current question in results
        try {
            debugLog("Attempting to parse questions_json");
            questions = [{"text": "A 36-year-old female newly diagnosed with HIV was treated with an Anti-HIV drug. She developed rashes & itching all over the body & swelling of lips the next day of treatment. The doctor diagnosed it as a hypersensitivity reaction to the Anti-HIV drug which was prescribed the day before. Which of the following Anti-HIV would be responsible for this reaction?", "options": [{"label": "A", "text": "Tenofovir", "correct": false}, {"label": "B", "text": "Emtricitabine", "correct": false}, {"label": "C", "text": "Abacavir", "correct": true}, {"label": "D", "text": "Lamivudine", "correct": false}], "correct_answer": "C. Abacavir", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Abacavir</p>\n<p><strong>Highyeild:</strong></p><p>Abacavir is a clinically potent ARV drug that acts after intracellular conversion to carbovir triphosphate, which gets incorporated in proviral DNA & terminates chain elongation. Hypersensitivity reactions such as rashes, fever, abdominal pain, bowel upset, and flu-like respiratory & constitutional symptoms occur in 2â€“5% of adult patients & are the major problems. A genetic basis & massive release of TNFÎ± have been related to this reaction. HLA 5701 association has been seen. Abacavir should never be given again to a patient who has developed this reaction.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: A. Tenofovir is the only nucleotide analogue that is a commonly used anti-HIV drug. It has a good tolerability profile & hence it is included in the preferred 1st line WHO regimen for adults & adolescents. Tenofovir-containing regimens have been found less toxic than other first-line Renal toxicity is to be watched. Option: B . Emtricitabine is a cytidine analogue which is converted intracellularly by cellular kinases into its triphosphate which acts as the HIV reverse transcriptase inhibitor. It is one of the least toxic ARV drugs; side effects are fatigue, headache, nausea, diarrhoea & discolouration of exposed skin. Dose reduction is needed for renal impairment. Option: D . Lamivudine inhibits HIV reverse transcriptase & results in chain termination. It is well tolerated & has a good safety profile, because of which it is accorded high priority in use for HIV. Side effects are headache, fatigue, rashes, nausea, anorexia, and abdominal pain.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 32-year-old male has been diagnosed with HIV-2 infection. The following Anti-HIV drugs can be given to this patient except:", "options": [{"label": "A", "text": "Emtricitabine", "correct": false}, {"label": "B", "text": "Efavirenz", "correct": true}, {"label": "C", "text": "Tenofovir", "correct": false}, {"label": "D", "text": "Ritonavir", "correct": false}], "correct_answer": "B. Efavirenz", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Efavirenz</p>\n<p><strong>Highyeild:</strong></p><p>Non-nucleoside reverse transcriptase inhibitors (NNRTIs), Entry (fusion) inhibitor & CCR5 receptor inhibitor acts against HIV-1 only, whereas Nucleoside reverse transcriptase inhibitors (NRTIs), Protease Inhibitors (PIs) & Integrase inhibitors are active against both HIV-1 & HIV-2. Efavirenz, being an NNRTI, is not active against HIV-2 & hence cannot be given in this case.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: A. Emtricitabine & Option C. Tenofovir are NRTIs; Option D. Ritonavir is a PI. Hence these drugs are active against both HIV-1 & HIV-2 and can be given in this case.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 62-year-old female came to the OPD with H/O of chronic fever, body aches & minimal weight loss. She has been diagnosed with HIV infection. The doctor prescribed her the drug Enfuvirtide. This drug belongs to the class:", "options": [{"label": "A", "text": "CCR5 receptor inhibitor", "correct": false}, {"label": "B", "text": "Integrase inhibitor", "correct": false}, {"label": "C", "text": "Entry (fusion) inhibitor", "correct": true}, {"label": "D", "text": "Protease inhibitor", "correct": false}], "correct_answer": "C. Entry (fusion) inhibitor", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Entry (fusion) inhibitor Entry (fusion) inhibitors , also known as fusion inhibitors, are a class of antiviral drugs that prevent a virus from entering a cell, for example, by blocking a receptor. Entry inhibitors are used to treat conditions such as HIV and hepatitis D</p>\n<p><strong>Highyeild:</strong></p><p>Enfuvirtide is an entry (fusion) inhibitor which acts by binding to HIV-1 envelope transmembrane glycoprotein (gp41) which is involved in the fusion of viral & cellular membranes. Fusion of the two membranes is thus prevented & entry of the virus into the cell is blocked. It is not active against HIV-2. Administered SC twice daily, it is used as an add-on drug to an optimized regimen in selected patients who have failed many earlier regimens/ have multidrug-resistant HIV & for whom there is no other treatment option. The injections are painful & cause local nodules/cysts. The cost & inconvenience are prohibitive and thus, it is not used in routine clinical practice.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: A . CCR5 receptor inhibitor CCR5 receptor antagonists are a class of small molecules that antagonize the CCR5 receptor. The C-C motif chemokine receptor CCR5 is involved in the process by which HIV, the virus that causes AIDS, enters cells. Hence antagonists of this receptor are entry inhibitors and have potential therapeutic applications Option: B. Integrase inhibitor Integrase inhibitors (INIs) are a class of antiretroviral drug s designed to block the action of integrase, a viral enzyme that inserts the viral genome into the DNA of the host cell. Since integration is a vital step in retroviral replication, blocking it can halt the further spread of the virus. Option: D. Protease inhibitors are medications that act by interfering with enzymes that cleave proteins. Some of the most well-known are antiviral drugs widely used to treat HIV/AIDS hepatitis C and COVID-19. These protease inhibitors prevent viral replication by selectively binding to viral proteases (e.g. HIV-1 protease)</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 56-year-old male, a known case of dyslipidemia was diagnosed with HIV. The doctor wants to prescribe him a Protease Inhibitor (PI). Which of the following PI can be given to this patient?", "options": [{"label": "A", "text": "Lopinavir", "correct": false}, {"label": "B", "text": "Ritonavir", "correct": false}, {"label": "C", "text": "Atazanavir", "correct": true}, {"label": "D", "text": "Saquinavir", "correct": false}], "correct_answer": "C. Atazanavir", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Atazanavir</p>\n<p><strong>Highyeild:</strong></p><p>The particular concern of PI is lipodystrophy (abdominal obesity, buffalo hump with wasting of limbs and face), and dyslipidaemia (raised triglycerides & cholesterol) which may necessitate restriction of lipids in diet. Dyslipidaemia & other metabolic complications are minimal with Atazanavir, but jaundice occurs in some patients without liver damage due to inhibition of hepatic glucuronyl transferase. Here, the patient is a known case of dyslipidaemia & hence PI having minimal effect on lipid profile like atazanavir can be prescribed compared to other PIs.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option A. Lopinavir, Option B. Ritonavir & Option D. Saquinavir are PIs having lipid abnormalities & metabolic syndrome as a major adverse effect. Hence, they should not be prescribed in this given case of dyslipidaemia.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 45-year-old female has been suffering from both HIV & Hepatitis B infection. Which of the following drug can be given to this patient?", "options": [{"label": "A", "text": "Lamivudine", "correct": true}, {"label": "B", "text": "Efavirenz", "correct": false}, {"label": "C", "text": "Indinavir", "correct": false}, {"label": "D", "text": "Nevirapine", "correct": false}], "correct_answer": "A. Lamivudine", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Lamivudine</p>\n<p><strong>Highyeild:</strong></p><p>The three anti-HIV drugs that are active against HBV also are lamivudine emtricitabine tenofovir</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: B. Efavirenz is a 1st generation non-Nucleoside reverse transcriptase inhibitor (NNRTI) used in HIV infection only (Not in HBV). Option: C. Indinavir is a Protease inhibitor (PI) used in HIV infection only (Not in HBV). Option: D . Nevirapine, a NNRTI is active against HIV infection only (Not in HBV).</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 32-year-old male has been brought to the OPD by his mother. His mother complains that he is a chronic IV drug abuser for 2 years & now he has started to have sex with sex workers also for the past few days. She is in constant fear that he would contract any disease like HIV. What regimen can be given to this patient as a prophylaxis?", "options": [{"label": "A", "text": "Tenofovir + Efavirenz + Lamivudine", "correct": false}, {"label": "B", "text": "Abacavir + Efavirenz + Lamivudine", "correct": false}, {"label": "C", "text": "Tenofovir + Emtricitabine", "correct": true}, {"label": "D", "text": "Tenofovir + Emtricitabine + Dolutegravir", "correct": false}], "correct_answer": "C. Tenofovir + Emtricitabine", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Tenofovir + Emtricitabine</p>\n<p><strong>Highyeild:</strong></p><p>This regimen is used for pre-exposure prophylaxis to people at high risk of contracting HIV infection. Key risk groups are Men who have sex with men, sex workers, Injection drug users, transgender people, and uninfected partners of heterosexual serodiscordant(one person is HIV positive and the other is HIV negative) couples.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: A. Tenofovir + Efavirenz + Lamivudine is the 1st line regimen now approved by NACO & it is given to HIV-positive patients irrespective of the CD4 cell count. Option: B. Abacavir + Efavirenz + Lamivudine should be given to the patient with renal failure instead of the normal regimen since tenofovir will cause renal toxicity. Option: D. Tenofovir + Emtricitabine + Dolutegravir: This regimen is used for post-exposure prophylaxis to Health care workers & others who get accidentally exposed to the risk of HIV infection by needlestick/ other sharp injury/ contact with blood/ biological fluid of HIV patients/ blood transfusion.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 43-year-old man with a long history of AIDS came to the ART centre and was found to have a CD4+ lymphocyte count of 110 cells/mm3 (normal > 500 cells/m m3) despite his current highly active antiretroviral therapy. The doctor decided to change the therapy and include a drug that blocks the integration of reverse-transcribed HIV DNA into the chromosomes of host cells. Which of the following drugs was most likely given?", "options": [{"label": "A", "text": "Zidovudine", "correct": false}, {"label": "B", "text": "Atazanavir", "correct": false}, {"label": "C", "text": "Lopinavir", "correct": false}, {"label": "D", "text": "Raltegravir", "correct": true}], "correct_answer": "D. Raltegravir", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Raltegravir Reason- Raltegravir is an integrase inhibitor. Drugs from this class block the transfer of reverse-transcribed HIV DNA into the chromosomes of host cells, thus preventing the final step of provirus integration. It is used mainly when standard antiretroviral therapy is not effective for a given patient, as in this case.</p>\n<p><strong>Highyeild:</strong></p><p>Raltegravir (Isentress â„¢) Adverse Effects Most Common Diarrhea Nausea Headache Fever Myopathy Elevated liver enzymes Especially in those co-infected with Hepatitis B or C</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: A. This drug is a reverse transcriptase inhibitor. Option: B , and  C. These drugs are protease inhibitors</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 35-year-old man with AIDS was recently diagnosed with cytomegalovirus retinitis, and therapy with ganciclovir was started. Two weeks later, the disease was not much improved, and the ophthalmologist decided to add a drug that, unlike ganciclovir, can directly inhibit DNA polymerase without requiring activation by phosphorylation. Which of the following drugs was most likely prescribed?", "options": [{"label": "A", "text": "Acyclovir", "correct": false}, {"label": "B", "text": "Lopinavir", "correct": false}, {"label": "C", "text": "Ribavirin", "correct": false}, {"label": "D", "text": "Foscarnet", "correct": true}], "correct_answer": "D. Foscarnet", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Foscarnet</p>\n<p><strong>Highyeild:</strong></p><p>Foscarnet is an inorganic pyrophosphate analogue that inhibits viral DNA polymerase, RNA polymerase, and HIV reverse transcriptase directly without requiring activation by phosphorylation. The drug, given only by intravenous injection, is effective in the treatment of cytomegalovirus (CMV) infections, including retinitis, colitis, and esophagitis. It is often given together with ganciclovir because it has been shown that the combination is superior to either agent alone in delaying the progression of retinitis.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: A, B, C. None of these drugs are effective in CMV retinitis</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 30-year-old woman with AIDS had been taking an antiretroviral therapy that included zalcitabine and stavudine. Which of the following adverse effects would be predicted to be most likely, as it is shared by both drugs?", "options": [{"label": "A", "text": "Nephrolithiasis", "correct": false}, {"label": "B", "text": "Myelosuppression", "correct": false}, {"label": "C", "text": "Hallucinations", "correct": false}, {"label": "D", "text": "Peripheral neuropathy", "correct": true}], "correct_answer": "D. Peripheral neuropathy", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Peripheral neuropathy Peripheral neuropathy is a dose-limiting adverse effect of both zalcitabine and stavudine, which can occur in up to 30% of patients. It is slowly reversible upon the prompt discontinuation of the drug.</p>\n<p><strong>Highyeild:</strong></p><p>HIV PERIPHERAL NEUROPATHY Distal sensory polyneuropathy(DSPN) MC neuropathy in HIV/AIDS 33% patients of HIV/AIDS Present in 88% in autopsy With low CD4 count Stocking-glove sensory loss Mononeuritis multiplex Inflammatory demyeliting polyradiculopathy</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: A. Nephrolithiasis is a potential adverse effect of indinavir, not of zalcitabine and stavudine. Option: B . Myelosuppression is a typical adverse effect of zidovudine. Zalcitabine and stavudine very rarely cause myelosuppression. Option: C . Zalcitabine and stavudine easily enter the central nervous system, but hallucinations are not reported.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 30-year-old pregnant woman was admitted to the hospital at term for delivery. One week earlier, the woman was diagnosed with asymptomatic HIV. An oral dose of nevirapine was given to the woman at the onset of labour. Which of the following best explains the reason for this administration?", "options": [{"label": "A", "text": "To start a highly effective antiretroviral therapy", "correct": false}, {"label": "B", "text": "To reduce AIDS symptoms in the near future", "correct": false}, {"label": "C", "text": "To prevent bleeding after delivery", "correct": false}, {"label": "D", "text": "To prevent HIV transmission in the newborn", "correct": true}], "correct_answer": "D. To prevent HIV transmission in the newborn", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>To prevent HIV transmission in the newborn</p>\n<p><strong>Highyeild:</strong></p><p>It is known that HIV can be transmitted to the fetus or newborn during pregnancy, delivery, or breastfeeding. It has been shown that certain antiretroviral drugs when given to the mother and the newborn during the perinatal period, can prevent the transmission of HIV. Zidovudine, given for 6 weeks before delivery, was used in the past, but recently it has been found that nevirapine is more convenient, as a single dose of the drug is effective when administered to women at the onset of labour and followed by an oral dose to the neonate within 3 days after the delivery.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: A. A highly effective antiretroviral therapy (HAART) usually includes more than one drug. Option: B. A single dose of an antiretroviral drug cannot prevent AIDS. Option: C. Nevirapine is not an oxytocic drug. Moreover, oxytocic drugs are given after the delivery, not at the onset of labour</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 28-year-old man recently diagnosed with AIDS started an antiretroviral therapy that included lopinavir. Which of the following steps of the viral growth cycle was primarily inhibited by this drug?", "options": [{"label": "A", "text": "Entry", "correct": false}, {"label": "B", "text": "Uncoating", "correct": false}, {"label": "C", "text": "Transcription", "correct": false}, {"label": "D", "text": "Assembly", "correct": true}], "correct_answer": "D. Assembly", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Assembly</p>\n<p><strong>Highyeild:</strong></p><p>During the late stage of the HIV growth cycle, the gene products become immature budding particles. The immature core (noninfectious) is cleaved into smaller infectious particles by viral aspartate protease. Atazanavir is a protease inhibitor that blocks the proteolytic cleavage, preventing viral maturation. Unlike other protease inhibitors, it does not appear to be associated with the impairment of glucose and lipid metabolism.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: A, B, C. None of these steps is affected by protease inhibitors</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 46-year-old man with HIV disease presents to the clinic because of a change in the appearance of his face over the past couple of months since he started antiviral therapy. His face looks sunken, particularly in the cheeks. His arms also appear to be wasting, whereas his breast tissue seems larger. He is unsure why this occurred. What medication is most likely responsible for this patientâ€™s appearance?", "options": [{"label": "A", "text": "Efavirenz", "correct": false}, {"label": "B", "text": "Enfuvirtide", "correct": false}, {"label": "C", "text": "Nevirapine", "correct": false}, {"label": "D", "text": "Ritonavir", "correct": true}], "correct_answer": "D. Ritonavir", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Ritonavir</p>\n<p><strong>Highyeild:</strong></p><p>The patient is suffering from lipodystrophy, which is most commonly associated with protease inhibitors used for HIV therapy. Ritonavir is a protease inhibitor. Protease inhibitors are thought to inhibit lipid metabolism leading to lipodystrophy. Lipodystrophy has been associated with nucleoside reverse transcriptase inhibitors; however, it is more common with protease inhibitors.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option : A. Efavirenz is a nonnucleoside reverse transcriptase inhibitor that is more likely to cause bone marrow suppression, not lipodystrophy. Option : B. Enfuvirtide is a fusion inhibitor that is more likely to cause injection site reactions, not lipodystrophy. Option : C. Nevirapine is a nonnucleoside reverse transcriptase inhibitor that is more likely to cause bone marrow suppression, not lipodystrophy.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 32-year-old woman found out 1 month ago that she has HIV disease. She began a HAART regimen after learning about her HIV status. Now she presents with nausea, vomiting, and abdominal pain. Serum amylase is elevated. If her condition is related to her medications, which drug is most likely the cause of her symptoms?", "options": [{"label": "A", "text": "Didanosine", "correct": true}, {"label": "B", "text": "Efavirenz", "correct": false}, {"label": "C", "text": "Emtricitabine", "correct": false}, {"label": "D", "text": "Nevirapine", "correct": false}], "correct_answer": "A. Didanosine", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Didanosine The patient on HAART therapy with nausea, vomiting, and abdominal pain with elevated serum amylase likely has pancreatitis. Pancreatitis is a known side effect of many antiretrovirals including didanosine. Didanosine should be discontinued in a patient who develops pancreatitis.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option : B. Efavirenz can cause CNS side effects such as dizziness and insomnia as well as a skin rash. It is not known to cause pancreatitis. Option : C. Emtricitabin e can cause GI side effects such as nausea, diarrhoea, and abdominal pain. It is not known to cause pancreatitis. Option : D. Nevirapin e can cause a skin rash that may be accompanied by liver damage. A patient taking nevirapine who develops a skin rash should have his or her liver enzymes checked. It is not known to cause pancreatitis.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}];
            if (!Array.isArray(questions) || questions.length === 0) {
                throw new Error("Questions data is empty or invalid");
            }
            debugLog(`Successfully parsed ${questions.length} questions`);
        } catch (e) {
            console.error("Failed to parse questions_json:", e);
            document.getElementById(